Navigation Links
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Date:2/6/2008

rade 3/4 elevated total bilirubin reported among atazanavir recipients in each of the groups, respectively. There were no opportunistic infections reported in the vicriviroc groups compared to two in the control group, and no systemic malignancies reported in any of the groups in the 48- week study.

These results supported the selection of the 30 mg once-daily vicriviroc dose for use in ongoing Phase III clinical studies.

About Vicriviroc Ongoing Phase III Studies

Building on the results of the VICTOR-E1 study, Schering-Plough is currently enrolling patients in two large global Phase III clinical studies with vicriviroc administered once-daily as a single 30 mg tablet in adult treatment-experienced HIV patients with R5-type virus only.

The two ongoing Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV-Infected Treatment-Experienced Subjects), evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The optimized background therapy must include at least two drugs to which the patient's HIV is susceptible. Patients coinfected with hepatitis B or C may be included in these studies and there are no exclusions of commonly prescribed drugs or need for dose adjustments based on the known vicriviroc drug-drug interaction profile. The two studies are currently enrolling approximately 375 patients each at more than 160 sites in North America, Latin America, Europe, Australia and South Africa.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own bi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
4. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
5. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... WASHINGTON, D.C. and ATLANTA (PRWEB) October 01, ... and information security executive networking and relationship-marketing ... the 2014 Information Security Executive® and Project ... Executives include top-ranking decision makers representing organizations ... and academics. Projects include large-scale technology endeavors ...
(Date:10/1/2014)... Between 23 million and 50 million people suffer ... from the National Institutes of Health (NIH) and the ... them have something else in common: They have a ... Gluten Free Therapeutics, makers of CeliVites nutritional supplements, ... publishing a series of blog posts aimed at educating ...
(Date:10/1/2014)... Scientists at the University of Western Australia say ... proteins has the power to knock out mesothelioma in ... new study on their website. Click here to ... UWA School of Pathology and Laboratory Medicine administered anti-CD25, ... with promising results. , “A timed triple immunotherapy ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 ... will speak to a group of dental specialists who ... the northern Spain city of Oviedo. Dr. Reshad of ... and lecturer with clients on two continents, will give ... and aesthetic full mouth reconstruction. , “These specialists want ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... cooking utensils may damage the environment, a new study ... of chemicals known as fluorinated polymers whose non-stick properties ... ,However, when heated, these polymers can emit ... toxic to plants and does not break down in ...
... new bacterial genome sequence suggests a route to new ... evade antibiotics, even minor infections can become a major ... to tackle resistant bacteria.// ,Antibiotic resistance is a ... antibiotics come from the soil bacteria Streptomyces , including ...
... report in The Journal of the American Medical Association. ... levels with a diet supplement of folic acid alone ... University of California at San Francisco and colleagues used ... cost effectiveness of lowering levels of homocystine through grains ...
... brain can grow new blood vessels after a minor stroke, which ... tries to heal itself after a stroke. We know that people ... cases. Now a study in laboratory rats reveals that the blood ... ,Researchers at the Harvard University School of Medicine in the US ...
... nitric oxide, a hormone involved in blood pressure control ... left untreated, it does not stay at one elevated ... to the researchers at the University of Texas, this ... oxide, which helps control blood pressure by dilating blood ...
... levels in men suffering from eating disorders. Men who ... than women with the same problems, researchers say.// ... the bones, which become dangerously thin and brittle. This ... essential nutrients, particularly calcium.Low bone mineral density (BMD) can ...
Cached Medicine News:
(Date:9/30/2014)... 2014 This study provides an analysis ... solutions including nuclear imaging informatics, PET imaging informatics, ... assesses the size of the market based on ... projects future growth based on the current drivers ... place in the broader markets for imaging equipment, ...
(Date:9/30/2014)... -- Decision Resources Group finds that the Asia Pacific ... China , India , Japan ... 2023. Dental implant procedure volumes will grow as physicians are increasingly ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Puma Biotechnology, Inc., a development stage biopharmaceutical ... license the worldwide commercial rights to neratinib, a ... transduction through the epidermal growth factor receptors, ErbB1 ... is being studied in the neoadjuvant, adjuvant and ...
... Corp. (OTCQB: CYCA), leading the way to cost effective ... Erik Stephansen to President of its eHealth division.  Mr. ... part of the company,s recent launch of their CyttaConnect™ ... network and its partners, FDA approved Bluetooth medical devices. ...
Cached Medicine Technology:Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5New Leader for CyttaConnect™ Medical Monitoring eHealth Division 2New Leader for CyttaConnect™ Medical Monitoring eHealth Division 3
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Regular tip. 1 mm x 13 mm. Serrated. Insulated....
Colibri style with 1.5 mm long angled tip and 0.12 mm teeth. Serrated handles with polished finish....
Straight shafts with 4 mm jaws. Serrated handle with dull finish. Jaws straight....
Medicine Products: